MEZODERMA - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 36,250 | 48,630 | 35,731 | 58,510 | 52,708 | 51,115 | 64,829 | 71,060 |
| Profit before tax | 2,495 | 7,784 | -5,404 | 14,314 | 4,784 | -17,072 | -7,893 | -779 |
| Net profit | 2,372 | 7,351 | -5,459 | 13,778 | 4,540 | -17,072 | -7,893 | -779 |
| Equity | 4,484 | 11,835 | 1,671 | 15,449 | 19,989 | 2,917 | -4,976 | -5,755 |
| Liabilities | 4,886 | 5,425 | 6,715 | 7,737 | 4,056 | 6,740 | 14,344 | 15,792 |
| Non-current assets | 3,954 | 3,032 | 2,236 | 2,090 | 2,381 | 1,039 | 1,144 | 741 |
| Current assets | 5,177 | 14,173 | 6,084 | 20,767 | 21,213 | 8,264 | 7,870 | 9,023 |
| Total assets | 9,131 | 17,205 | 8,320 | 22,857 | 23,594 | 9,303 | 9,014 | 9,764 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 7,724 | 8,377 | 6,018 |
|
Financial indicators
|
||||||||
| Revenue change y/y | -13.3% | +34.2% | -26.5% | +63.8% | -9.9% | -3.0% | +26.8% | +9.6% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 26.0% | 42.7% | -65.6% | 60.3% | 19.2% | -183.5% | -87.6% | -8.0% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 52.9% | 62.1% | -326.7% | 89.2% | 22.7% | -585.3% | - | - |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 6.5% | 15.1% | -15.3% | 23.5% | 8.6% | -33.4% | -12.2% | -1.1% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 6.9% | 16.0% | -15.1% | 24.5% | 9.1% | -33.4% | -12.2% | -1.1% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 1.1 | 0.5 | 4.0 | 0.5 | 0.2 | 2.3 | - | - |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 36,250 | 48,630 | 35,731 | 58,510 | 52,708 | 51,115 | 64,829 | 71,060 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
MEZODERMA - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-02-18 | 2026-03-11 | 5.86 |
| 2022-12-16 | 2022-12-29 | 1.34 |
| 2022-11-21 | 2022-12-12 | 1.34 |
| 2022-11-17 | 2022-11-18 | 1.34 |
| 2022-10-28 | 2022-11-07 | 1.34 |
| 2022-07-18 | 2022-07-26 | 398.24 |
MEZODERMA - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
MEZODERMA, UAB (code 302595902) is a Private Limited Liability Company engaged in medical specialists activities. In 2025, the company generated revenue of €71.1K, up 9.6% year on year and 39.0% compared with 2023. Despite the continued increase in turnover, the business remained loss-making, reporting a net loss of €779 in 2025 after losses of €7.9K in 2024 and €17.1K in 2023. The profit margin improved materially over the period, narrowing from -33.4% in 2023 to -12.2% in 2024 and -1.1% in 2025, indicating a move closer to breakeven. At the end of 2025, total assets stood at €9.8K, equity at -€5.8K and liabilities at €15.8K. Short-term assets accounted for €9.0K, while long-term assets were €741. Revenue per employee was €71.1K, and profit per employee was -€779, reflecting the company’s small scale and still fragile profitability.